In addition, we aimed to introduce POLE testing for certain cases of endometrial cancer: MMR deficient, p53-mutated, ER-negative, or stage 1b and above and to create a sustainable change in the long-term management of patients with endometrial cancer at RCHT. This evidence concerns the gene ESR1 and endometrial cancer.